Sharda Cropchem Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

3
R.V. Bubna (Chairman & Managing Director), Jetkin Gudhka (Company Secretary), Shailesh Mehendale (CFO)

Analysts

10
Anubhav Mukherjee (Prescient Capital), Deepak Poddar (Sapphire Capital), Himanshu Binani (Anand Rathi), Madhur Rathi (Counter Cyclical Investments), Nitin Shakdher (Green Capital), Riju Dalui (Antique Stock Broking), Rohit (iThought PMS), Rohit Nagraj (360 ONE Capital), Vikas Singh (Neo Capital), Viren Deshpande (Alphapeak Investments)

Financials & KPIs

Geographic & Segment Commentary

• Europe: Largest geography and traditionally highest-margin region. Revenue softened in Q1 due to distributors cutting stock after an unusually hot summer, following an exceptionally strong FY26. Importantly, agrochemical gross margins in Europe improved to 44.2% (vs 42.9% last year). Management confirmed distributor restocking has normalized and volumes should recover in coming quarters. Registrations: 1,682 (+3 QoQ).

• LATAM: Remained one of the strongest growth engines with robust volume growth, but gross margin fell sharply to 16.9% from 28.0% YoY — growth was volume-led with lower-margin product mix. Registrations flat at 760. Management cited weather and customer stocking decisions as key drivers but declined to provide detailed region-level economics.

• NAFTA: Strong growth in the quarter with gross margin expansion to 32.8% from 25.9% YoY — a significant margin improvement. Registrations: 325 (+2 QoQ). Management expects momentum to continue, though customer pre-buying cannot be ruled out.

• Rest of World: Delivered growth with margin expansion to 30.8% from 26.8% YoY. Registrations flat at 249. Benefited from improving pricing environment and favorable product mix.

Company-Specific & Strategic Commentary

• Registration-led growth platform: Total registrations of 3,016 with 1,027 pending approvals. Management reiterated annual investment of ₹450–500 crore in registration dossiers, with investments increasing this year. Registration process acknowledged as uncertain — timelines and costs depend on global regulators; Q1 FY27 royalty spent ₹273 crore including one-off data compensation costs.

• Asset-light contract manufacturing model: Company manufactures nothing anywhere in the world, including India — 100% contract manufacturing, primarily sourced from China. All products are sold under Sharda's own registrations across geographies.

• New product strategy: Newer molecules contribute to margin improvement more than volume initially, as customer acceptability builds gradually while older products fade. No fixed internal benchmark for new product launches given regulatory unpredictability.

• Improving pricing environment: Prices, which took a severe beating two years ago, have stabilized and are improving slowly across markets — supporting margin outlook.

• Balance sheet strength: Debt-free with cash, bank, and liquid investments of ₹767 crore; working capital days improved by 10 days QoQ to 88 days. Political/macro factors continue to make cross-currency movements unpredictable, but sourcing in USD and selling in multiple currencies is core to the model.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Revenue Growth Decomposition

• Question: Can you split the 9% revenue growth into volume, FX, and realization/mix? (Anubhav Mukherjee)
• Answer: Volume was -1.6%, FX impact +12.7%, and product mix -2.1%, totaling +9%. The negative mix reflects the degrowth in Europe (higher-margin products) offsetting growth in other geographies; expected to improve in coming quarters. (Shailesh Mehendale)

Forex Gain Accounting Treatment

• Question: What drives the quarterly forex gain and loss, and how is it accounted? (Anubhav Mukherjee)
• Answer: The unrealized gain/loss comes from re-pricing foreign currency trade receivables and payables at each balance sheet date. Q1 FY26 was exceptional — Euro-USD appreciated ~10% in that quarter; current quarter saw only ~1% movement. Forex gains/losses are excluded from EBITDA. (Shailesh Mehendale)
• Question: Could the company present like-to-like PAT excluding forex for fairer comparison? (Nitin Shakdher)
• Answer: Management acknowledged the concern and said they will consider adding more clarity in future presentations, noting the current practice already discloses PBT excluding forex impact in the investor presentation. (Shailesh Mehendale)

Europe Restocking & Business Model

• Question: Has distributor restocking improved as of now, and does the company import raw materials? (Deepak Poddar)
• Answer: Restocking has improved and in most cases reached normal levels. On the business model: Sharda does not manufacture anything anywhere in the world — 100% contract manufacturing, mainly from China, so there is no import question in India. (R.V. Bubna)

Registration Momentum & Capex Guidance

• Question: Registration additions have slowed in the past three years — how should investors look at growth? (Madhur Rathi)
• Answer: The registration process is full of uncertainties — timelines and costs depend on regulators. The company continues investing ₹450–500 crore annually (increasing this year) and sees no pressure on existing molecules; Europe's Q1 softness was weather-driven, not molecule-driven. (R.V. Bubna)
• Question: Q1 registration capex was ₹273 crore vs ₹500 crore guidance — revised? (Vikas Singh)
• Answer: No revision. Q1 included heavy one-off data compensation costs that will not repeat; full-year investment is expected at ₹480–550 crore. (R.V. Bubna)

New Product Contribution

• Question: What is the revenue contribution from products launched in the last 12–18 months? (Rohit, iThought PMS)
• Answer: New products contribute more to margins than to volumes initially, as customer acceptability takes time. There is no fixed internal benchmark for new product additions given regulatory unpredictability. (R.V. Bubna)

FY27 Margin Guidance

• Question: With Q1 gross margin at 37% despite lower Europe, what is the full-year view? (Riju Dalui, Antique Stock Broking)
• Answer: Full-year gross margin guidance is 35–37%, with EBITDA margin of 18–20%. Management declined to provide region-level detailed calculations on the call, but confirmed the overall framework. (R.V. Bubna)

Region-wise Gross Margins & Pre-buying

• Question: Can you share region-wise gross margins for Q1 FY27 vs Q1 FY26? (Himanshu Binani)
• Answer: Europe 44.2% vs 42.9%; NAFTA 32.8% vs 25.9%; LATAM 16.9% vs 28.0%; Rest of World 30.8% vs 26.8%; total 36.7% vs 35.5%. (Shailesh Mehendale)
• Question: Is strong NAFTA/LATAM growth partly pre-buying that will normalize in Q2–Q3? (Rohit Nagraj)
• Answer: Customers sometimes stock ahead when prices are attractive and product availability is assured, but management sees no strong overarching trend — it varies by individual customer. (R.V. Bubna)

Tax Rate, Depreciation & Pricing Trends

• Question: Why was the effective tax rate high at ~26% in Q1, and what is the D&A outlook? (Viren Deshpande)
• Answer: Annualized effective tax rate will normalize to 18–20% as overseas subsidiary tax rates blend with the Indian holding company; Q1 was a quarterly aberration. D&A will trend higher at ~₹370–375 crore for FY27 vs ₹325 crore in FY26, reflecting continued amortization of registration intangibles. (Shailesh Mehendale)
• Question: What are the pricing trends across markets? (Anubhav Mukherjee follow-up)
• Answer: Prices are improving — they took a severe beating two years ago, stabilized, and are now slowly recovering. The Q1 realization degrowth was primarily product-mix driven due to lower Europe revenue. (R.V. Bubna)

Key Takeaway

Sharda Cropchem delivered a strong operating quarter with revenue of ₹1,074 crore (+9% YoY) and EBITDA of ₹178 crore (+25%), though reported PAT fell to ₹88 crore from ₹143 crore largely on a swing in unrealized forex gains (₹7.5 crore vs ₹73.1 crore); like-to-like PBT grew 16% to ₹111 crore. European revenues softened on heat wave-driven destocking but gross margins expanded to 44.2%, while NAFTA (32.8%) and Rest of World (30.8%) margins improved and LATAM grew volumes at sharply lower margins (16.9%). Management reaffirmed FY27 guidance of 10–15% revenue growth, 35–37% gross margins, and 18–20% EBITDA margins, underpinned by 3,016 registrations, 1,027 pending approvals, ₹767 crore of cash on a debt-free balance sheet, and registration investment of ₹480–550 crore. The outlook hinges on European volume recovery, pricing momentum after a two-year downturn, and stability in cross-currency movements, with registration approval timelines and weather conditions remaining the key watch points.

Transcript was complete. Call date not specified in the transcript provided.